NCT00968591已完成1 期
An Open-label, Single-dose Study to Assess the Pharmacokinetics of Oral Everolimus (Afinitor®) in Subjects With Impaired Hepatic Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Evaluate the pharmacokinetics of a single oral dose of everolimus in subjects with severely impaired hepatic function (Child-Pugh C) relative to healthy controls. Measure: AUC, Cmax, tmax, λz, Vd/F, CL/F and t1/2
研究概览
简要总结
This clinical pharmacology research study will assess the safety and pharmacokinetics of the drug everolimus in patients with impaired hepatic function as compared to healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects:
- •In good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory test values (except for values related to hepatic insufficiency).
- •Hepatic impaired subjects:
- •A Child-Pugh Classification score clinically determined as Class A, Class B, or Class C.
- •Absolute neutrophil count (ANC) > 1000 cells/mm3
- •Hemoglobin > 9 mg/mL
- •Platelet count > 50,000/mm3 at screening and baseline
- •Serum creatinine ≤ 2.0 x ULN
- •Free of significant medical disorders unrelated to the subject's hepatic disorder
排除标准
- •All subjects:
- •Significant illness, including infections, or hospitalization within 4 weeks prior to dosing (hospitalization is allowed for hepatic impaired subjects if related to liver disease). Invasive systemic fungal infections need to be fully resolved prior to study entry.
- •History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
- •History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug (everolimus) or drugs similar to the study drug (other mTOR inhibitors, e.g., rapamycin or temsirolimus).
- •Active bleeding during the last 28 days prior to dosing, including variceal bleeding.
- •Except for hepatic impairment, any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study.
- •Use of tobacco within 7 days prior to dosing or during the study.
- •Consumption of alcohol within 3 days prior to dosing or during the study.
- •Consumption of grapefruits, grapefruit juice, Sevilla oranges, starfruit or related foods within 7 days prior to dosing or during the study period.
- •Use of any drugs known to affect CYP3A4 or PgP, including both inhibitors and inducers, within 7 days prior to dosing or during the study.
- •Hepatic impaired subjects:
- •Symptoms or history of Grade 3 or 4 hepatic encephalopathy within 4 weeks of study entry.
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
RAD001
Experimental
干预措施: Everolimus (Drug)
结局指标
主要结局
Evaluate the pharmacokinetics of a single oral dose of everolimus in subjects with severely impaired hepatic function (Child-Pugh C) relative to healthy controls. Measure: AUC, Cmax, tmax, λz, Vd/F, CL/F and t1/2
时间窗: First 8 days
次要结局
- Explore correlation between pharmacokinetics and hepatic function parameters(First 8 days)
- Evaluate the pharmacokinetics of a single oral dose of everolimus in subjects with mild and moderate impaired hepatic function (Child-Pugh A and B, respectively) relative to healthy controls.(First 8 days)
- Assess the safety and tolerability of a single oral dose of everolimus in subjects with impaired hepatic function (Child-Pugh A, B, and C).(First 8 days plus day 15 and day 28 post-dose follow-ups for safety)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal ImpairmentRenal ImpairmentNCT05497297Haisco Pharmaceutical Group Co., Ltd.42
已完成
1 期
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese VolunteersHealthy VolunteersHemophilia ANCT03380780Hoffmann-La Roche16
已完成
2 期
Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLIActivated PI3K-delta SyndromeNCT02593539GlaxoSmithKline5
尚未招募
2 期
MRG-001 in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisLou Gehrig DiseaseMotor Neuron AtrophyMotor Neuron DiseaseNCT06315608MedRegen LLC10
已完成
1 期
Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532HealthyType 2 Diabetes MellitusNCT01369602Pfizer27